On 17 November 2026, the US Food and Drug Administration (FDA) granted accelerated approval to neladalkib (brand name Nelkarmi, formerly NVL-655). It is approved for adults with advanced ALK-positive non-small cell lung cancer (NSCLC) who have already received certain ALK treatments.
Neladalkib is a new-generation ALK inhibitor developed by Nuvalent, now part of GSK. It is not yet approved in Europe.
What is neladalkib?
Neladalkib is a targeted treatment, taken as a tablet, that blocks the ALK protein driving ALK-positive lung cancer. It was designed to:
- stay active against ALK resistance mutations that can develop during earlier ALK treatments
- reach the brain, a common site of spread in ALK-positive lung cancer
- minimise certain off-target side effects
What did the ALKOVE-1 trial show?
The approval is based on ALKOVE-1, a global phase I/II trial. The main analysis included 222 people with previously treated ALK-positive NSCLC. It was a single-arm trial: everyone received neladalkib, and there was no comparison group.
| Alectinib as the only previous ALK inhibitor | At least two ALK inhibitors and platinum-based chemotherapy | |
|---|---|---|
| Patients | 67 | 155 |
| Tumour response | 49% (33 of 67) | 32% (50 of 155) |
| Responders still responding at 6 months | 76% | 69% |
| Responders still responding at 12 months | 52% | 51% |
| Brain response, in people with measurable brain metastases | 55% (11 of 20), including 25% complete responses | 26% (14 of 53), including 11% complete responses |
A tumour response means the tumours shrank by at least 30% or disappeared on scans, as assessed by independent reviewers.
Side effects
The most common side effects, each seen in at least 1 in 5 patients, were:
- liver problems (hepatotoxicity)
- muscle and bone pain
- constipation
- changes in taste
- tingling or numbness in the hands and feet (peripheral neuropathy)
- swelling (oedema)
- fatigue
5% of patients stopped neladalkib permanently because of side effects, most often because of liver problems.
Who is it approved for in the US?
Adults with locally advanced or metastatic ALK-positive NSCLC who have received either:
- alectinib as their only previous ALK inhibitor, or
- two or more ALK inhibitors and platinum-based chemotherapy.
What does accelerated approval mean?
The FDA uses accelerated approval for medicines that treat serious conditions with an unmet need. The decision is based on early evidence, such as how often tumours shrink. Further evidence is required to confirm the clinical benefit, and the FDA can withdraw the approval if that benefit is not confirmed.
What does this mean for patients in Belgium?
Neladalkib is not yet available through standard care in Belgium. It first needs European approval, then a reimbursement decision by INAMI/RIZIV, before it can be routinely prescribed and reimbursed here.
Compassionate use. Nuvalent runs a compassionate use programme for neladalkib in several European countries, but it is not currently available in Belgium. The programme is for people who have already received at least one ALK inhibitor, have no suitable alternative treatment and cannot join a neladalkib clinical trial.
Clinical trials. The phase III ALKAZAR trial compares neladalkib with alectinib as a first treatment for people who have not yet received an ALK inhibitor. The EU Clinical Trials Information System (CTIS) lists the trial as recruiting in Belgium at three sites: Cliniques universitaires Saint-Luc (Brussels), UZ Leuven and UZA (Antwerp University Hospital). Eligibility criteria apply, so ask your oncologist whether this trial could be an option for you.
CTIS also lists ALKOVE-1, the trial for people who have already received ALK inhibitors, as recruiting in Belgium at UZ Leuven and UZA (Antwerp University Hospital). Ask your oncologist whether it is still open.
Why this matters
For people living with ALK-positive lung cancer, having more treatment options matters. Resistance to ALK inhibitors remains a challenge, and every new treatment brings the possibility of longer disease control.
ALK Positive Belgium will keep following developments on European approval and access for patients in Belgium, and will update this page when there is news.
Sources
- GSK press release: Nelkarmi (neladalkib) approved in the US, 17 November 2026
- ALKOVE-1 (EU CT 2024-514266-39-00), EU Clinical Trials Information System
- ALKAZAR (EU CT 2024-517553-26-00), EU Clinical Trials Information System
- Neladalkib expanded access programme (NCT06834074), ClinicalTrials.gov
This article is for information only and does not replace advice from your medical team.